logo

FDA Calendar

Share
Company Name Blueprint Medicines
Drug Name Pralsetinib (NDA)
Event Name FDA decision on Pralsetinib for the treatment of advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer
Event Date 02/28/2021
Outcome Date
Outcome
Drug Status Reviewed under the FDA's Real-Time Oncology Review (RTOR) pilot program
Rival Drugs
Market Potential
Other Approvals Pralsetinib approved by the FDA under the brand name GAVRETO for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
News
Return to FDA Calendar